Terazosin

Terazosin

Systematic (IUPAC) name
6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine
Clinical data
Trade names	Hytrin
AHFS/Drugs.com	monograph
MedlinePlus	a693046
Pregnancy cat.	?
Legal status	?
Pharmacokinetic data
Protein binding	90-94%
Half-life	12 hours
Identifiers
CAS number	63590-64-7 Y
ATC code	G04CA03
PubChem	CID 5401
DrugBank	DB01162
ChemSpider	5208 Y
UNII	8L5014XET7 Y
KEGG	D08569 Y
ChEBI	CHEBI:9445 Y
ChEMBL	CHEMBL611 Y
Synonyms	[4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-tetrahydrofuran-2-yl-methanone
Chemical data
Formula	C19H25N5O4
Mol. mass	387.433 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22) Y Key:VCKUSRYTPJJLNI-UHFFFAOYSA-N Y
Y (what is this?)  (verify)

Terazosin (marketed as Hytrin or Zayasel) is a selective alpha 1 antagonist used for treatment of symptoms of an enlarged prostate (BPH). It also acts to lower the blood pressure, and is therefore a drug of choice for men with hypertension and prostate enlargement.

It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls.

Most common side effects include dizziness, drowsiness, headache, constipation, loss of appetite, fatigue, nasal congestion or dry eyes, but they generally go away after only a few days of use. Therapy should always be started with a low dose to avoid first dose phenomenon. Sexual side effects are rare, but may include priapism or erectile dysfunction.